The Food and Drug Administration has approved PARP inhibitors to treat metastatic prostate cancer patients with DNA repair deficiencies due to pathogenic variants in genes involved in homologous recombination repair (HRR), including BARD1. Here, BARD1 is linked to Familial prostate cancer.